Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.64 |
| ▸ | PRNP | P04156 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.44 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640469 | 1.00 | MPO (0.64) | MPOPRNPCYP1A2CYP2D6CYP26A1 | |
| SCHEMBL9616248 | 0.83 | MPO (0.53) | MPOCYP19A1CYP11B2KDM4EMAPT | |
| SCHEMBL28323713 | 0.82 | MPO (0.44) | MPOPRNPCYP1A2CYP2D6CYP26A1 | |
| SCHEMBL316976 | 0.81 | MPO (0.66) | MPOCYP1A2CYP2D6CYP26A1ELANE | |
| SCHEMBL12119770 | 0.81 | MPO (0.66) | MPOCYP1A2CYP2D6CYP26A1ELANE | |
| SCHEMBL31285043 | 0.81 | MPO (0.66) | MPOCYP1A2CYP2D6CYP26A1ELANE | |
| SCHEMBL4802603 | 0.80 | MPO (0.60) | MPOCYP1A2CYP2D6ELANEABCB1 | |
| SCHEMBL27001686 | 0.79 | MPO (0.64) | MPOCYP1A2CYP2D6ELANEABCB1 | |
| SCHEMBL6858889 | 0.78 | MPO (0.57) | MPOCYP26A1CYP27A1ELANEKDM4E | |
| SCHEMBL17108416 | 0.77 | MPO (0.59) | MPOCYP1A2CYP2D6CYP26A1METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400499-A1 | GLUTARIMIDE COMPOUND AND USE THEREOF | Medshine Discovery Inc. (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-4310083-A1 | FURAN FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND | Medshine Discovery Inc. (CN) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023214325-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS | NOVARTIS AG (CH) | 2023-11-09 | — | — | WO | disclosed |
| EP-3848363-B1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | MEDSHINE DISCOVERY INC (CN) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022262782-A1 | GLUTARIMIDE-SUBSTITUTED ISOXAZOLE FUSED RING COMPOUND, AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2022-12-22 | — | — | WO | disclosed |
| EP-3848363-A1 | TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND | Medshine Discovery Inc. (CN) | 2021-07-14 | — | — | EP | disclosed |
| WO-2020070050-A1 | FUNGICIDAL 5-SUBSTITUTED IMIDAZOL-1-YL CARBINOL DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-09 | — | — | WO | disclosed |
| EP-1409476-B1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | GILMORE JEREMY (GB) | 2004-09-16 | — | — | US | disclosed |
| EP-0416038-B1 | NOVEL CHEMILUMINESCENT FUSED POLYCYCLIC RING-CONTAINING 1,2-DIOXETANES AND ASSAYS IN WHICH THEY ARE USED | TROPIX INC (US) | 1997-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | HTR1A, HTR5A, HTR1E | MPO 2781/4885PRNP 1199/4885CYP1A2 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.